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STUDIES ON CARCINOMA OF THE PROSTATE
1． INVESTIGATIONS ON THE EFFECTS OF
ANTIANDROGENIC TREATMENTS AND
SURVIVAL OF THE PATIENTS
                      Tsuguru Usur
From’～ie 1）ePartment〔ゾ乙乃’e～09ク， ffiroshima Universit］Schoolげ几fedi‘ine
              （Chairman ．’1）r｛ジH． A’ihira， M．1）．ノ
    Seventy patients With carcinoma of the Prostatc were treated at the Department of Urology，
Hiroshima UniVersity HQspital du血g the 10 years period，1967 tG 1976，
    1） The average age of the patients was 71．5 years． Mest of them had complaint cf difficulty
omlrination． Pain due to皿etastasis to the bone was seen i耳21．4％． Gardiovascular disease was
accompanied in 24．60／．．
    2） lntravenous pyelograms were abnormal in 20．70／o already before the treatment．
    3） Total serum acid phosphatase was elavated in 9．30／． of stage C cases and 74．20／． of stage D
cases． Prostatic serum acid phosphatase was elevated in 17．90／． of stage C and 62．10／． of stage D． Total
serum acid phosphatase was elevated in 68．00／， of the cases with meatstasis to the bone and in 16．70／o
of the cases without it． Prostatic serum acid phosphatase was elevated in 65．20／． and・20．5％， respec－
tively．
    4） ．The clinigal respons．e was seen iri 68．40／， of．the cases treated by antiandrogenic methods．
    5） Relative survival．rate of seventy cases at five and eight years was O．562 （±O．073） and O．190
（±0．055）．Relative survival rate at five years of the stage C and D． group was O．750（土0．OI4）and
O．283 （±O．093），’ respectively． ． Relative survival rate at 8 yeats showed no difference between two
groups．
    6） C4ses with bladder infilFration ’had shorter survival than those without it， but ，these
difference was not si．gnificant． Survival rate was not related with abnormalities on IVP apd with
the endoscopic’?奄獅р奄獅№刀D
    7） ’ Relative survival rate at five years showed significant difference between the cases with and
without bone metastasis．
    8） The relative survival rate was better， the higher the age at the first hospital visit．
    9） The cases which showed elevated total or prostatic serum acid phosphatase showed slight
tendency of poor survival． The cases in whi6h those phosphatasgs remained high despite estrogen
therapy showed extremely poor sUrvival．
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  10） The period required for progression from stage C to stage D was clinically 38．4 （±6．4） months．
  11） Forty cases were clear in ferms of causes of death． Twenty－four （60．00／．） of them died of
canber of the prostate． The causes other than cancer increased with aging of the patients．
  12） Death due to cardiovascular disease was not experienced even among the patients receiving
high rate of estrogen．
  13） The cases receiving high rate of estr6gen showed iow recurrence rate at two years． Period
from the recurrence to death was relatively long in these cases． ln stage C group， those treated with
high rate of estrogen showed longer period to the recurrence and death． ln stage D group， this was
not remarkable．
  14） At the time of recurrence of carcinoma of the prostate， total serum acid phosphatase was
abnormally high in 14 （73．70／o） of 19． Administration rate of estrogen did not affect the serum acid
























































らわした．その算定方法は internal symposium on















Table 1． Age distribution in patients with
     carcinoma of the prostate．


























Table 3．Finding of urograrns in patients with




No． of cases Per cent
100．0
Note： The youngest case； 50 years of age
  The oldest case： 87 years of age































Table 2． Symptoms and associated chronic
     diseases in patients with carcinoma
     of the prostate．















edetre of lower extremity 1















































Percentage of elevated total and
prostatic serum acid phosphatase
leveis in patients with carcinoma
of the prostate in relation to
clinical stage before treatment．







0／5★〔0｝禽貢   0／5 ｛0｝
3／31 （9．7） 5／28 ｛17．9｝
23／31 ｛74．2） 18／29 （62．V












±O．39， stage C 4．07．±0．91， stage D 18．73±5．14 KAU
であり，stage C， stage Dのそれぞれの平均値の間に
は統計学的に有意の差を認めた（Table 5）．．
Table 7． Clinical effectiveness of irnmediate
     castration and cstrQgen therapy in
     patients with carcinoma of the
     prostate five weeks after the start
     of antiandrogenic hormone therapy．
Clinica1


















of cases 5 31 31 67
Table 5． Mean totaI and prostatic seru皿acid
     phosphatase leveis in patients with
     carcinoma of the prostate in relation





Stage B （rF一，5） 2．88 ± O．39＋＊ 1．10 ± O．31
Stage C （n＝±31） 4．07 ± O．91 2．24 ± O． 94





ke btean plus or mirius stmdard error King－Arrnstrong Uni．t／di1
勲★欧比significant





Table 6． lnfluence of skeletal metastasis on
     total and prostatic serurn acid




17／25＊ （68．0）＊“ 15／23 ｛65．2）
7／42 （16．7） 8／39 （20．5）
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Fig． 3． aornparison of survival between two groups， with or without urinary stasis of



















      12345678          Survival in years

























N Without skeletal metastasis






減 へへ   、、（＼
NxNNて＞e一・一一一くkNNKNX）一一一一
      1 2345678           Survival in years














X一 N  ．  ＼ロ＜＼
‘A
                ●r＿＿＿●  Undey・65－year old
㌣＼   ＝二＝1瀦：端
  ＼  ㌔＼
    、、    ＼
     ＼  ＼【』．
       ヘ             へ り        、、     「へ                           し          ¶一一噸一聞く〉、
NNXN．
  x
    N’XN．
     ’眺＼
        ＼、鮨＼口
NM
  1       2      3      4 5      6      7
          Surviva1 in years
































H Vifithin normal range
O一一一 一〇 Elevated
’h－f．．Nx欺NN× 、て》
       123 45678              Survival in years




























  一一．   、つ一一一嘲○㌧           ．．一． ．一．． NO一一 一一 “XNNN、て）
       工2345678              Survival in years
Fig． 8． Survival based on prostatic serum acid phosphatase leveis before antiandrogenic
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 Stagc Cの13例がstage Dへ進行するまでの平均
Tab工e 8． Average periods for requiring progression
     to the clinical stage D through the stage













＊ tmths to progressian
＊＊ Average months to pregression
 （ mm plus or Tminus standard error ）
Table 9． Clinical effectiveness of irnmediate castration and estrogen therapy
     in patients with carcinoma of the prostate， comparison of changes
     of TSAP leve：s and clinical effectiveness．
Clinical
effectiveness
Changes of TSAP levels













rk TSAP levels before treatment














Table 10． Cause of death by age before
     treatment in patients with
     carcinoma of the prostate．
dause of death     Age             Tbtal赦）．wtOver 76 of caseg
［mad－p■て）statゴ．C da． 10嚢（83．4）嚢鳶
團轍5       工 〔 8●3）




3 （37．5） 24 ｛60．0｝
3 （37．5） 9 ｛22．5）
2 ｛25．0） 7 （17．5）
Tt；t al No． of cases 12 CIOO） 20 （100） 8 （100） 40 ｛XOO）






Influence of estrogen therapy on the cause of death in patients
with carcinoma of the prostate．
273
Cause of death
il．aj4一．一n－is．traeip．n． ．rate of estrogen

































Total No． of cases20 3 9 8
Table 12．Influence of administration rate of estrogen on the relapse and death in patients
with carcinoma of the prostate．
imist ration ）io． of
rate of estrogen cases
R∈血ssion and survi▽a工periods follσwing initial trea七ment面． ofi alived






















［Ebta1 bto． of cases 256／13 6／3 3／6 6／3 4


















































Frequency of abnormally elevated serum． acid phosphatase leveis at the onset of
relapse in patients with prostatic carcinoma．
Ad「・mi・trati㎝ Pre－tre・tment葦鹿墜一一（坤er 5 yrs・  ISI一？ 1evel・


































魑C）taユNb。 of cases   l4／l17／8 6 O／2 12 2／3 15 O／1 21 4 8
de NLmioer oE cases w Lth norma t serurn acid phosphatase levels／nurrilber oE cases with abnormal senrn acid
 画os函atase levels．
＊de N磁of died cases with prosta七ic carcin㎜
＊t“ Ntmber of alived cases over 5 yeqrs
Table 14．Remission and survival periods following initial treatment in relation





























34．8 ± 6．’4 （13－72）
46．3 ± 9．2 （18－72＞
21．0 ± 3．1 （13－31）
40．6 ± 6．9 〈16－66）
56．3 ± 7．3 （42－66）
25．0 ± 2．9 （16－34）
Tbtai No． of cases 2023．6 ± 3．7 〈5－57＞ 37．5 ± 4．6 （13－72）
de mm plus or minus standard emror months
k＊ Range
Table 15．Relationship among chief complaint and TSAP at relapse， b6ny
metastasis ．on initial treatment and remission periods．
Ch±ef oaErplaint NO． of Bony metastasiS on Elovated TSIV？ Remission

















































































































































































































































































































値（TSAP）はそれぞれstage B 2．88±O．39 KAU，
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